About the SaRNA & Circular RNA Therapeutics Event

What You Could Have Expected as RNA Came Full Circle in 2026

The 5th Circular & Self-Amplifying RNA Therapeutics Summit was designed for teams actively navigating the transition of circular and self-amplifying RNA from emerging modality to clinical reality.

As excitement gives way to execution, the field now faces a new set of challenges, including enabling durable expression, supporting redosing, aligning RNA design with delivery architecture, and building IND-ready CMC and regulatory strategies.

This highly-focused summit delivered three days of technical depth, strategic clarity, and peer-to-peer discussion, and brought together innovators from CirCode Biomed, Strand Therapeutics, Sail Biomedicines, Replicate Bioscience, HDT Bio, Chimeron Bio, Altamira Therapeutics, CSL, and leading academic institutions. The agenda prioritized real-world lessons, first-in-human data, and platform-level decision-making across discovery, translation, and development.

Attendees enjoyed:

• Clinical and translational data validating circRNA and saRNA durability and safety
• Deep technical sessions on delivery beyond LNPs, immunogenicity engineering, and redosing strategies
• Practical guidance on CMC readiness, IP positioning, and regulatory alignment
• Workshops designed to reduce IND risk and accelerate development timelines

Built for discovery scientists, platform leaders, translational teams, CMC and regulatory experts, and biotech decision-makers, this summit offered the insight and connections required to move next-generation RNA therapeutics forward with confidence.

Speaker presenting on SaRNA, Circular RNA and next‑generation RNA therapeutics at event

2026 Event Highlights

Validating Circular & Self-Amplifying RNA in the Clinic

Attendees examined first-in-human and translational data demonstrating durable expression, tissue selectivity, and clinically relevant dosing across emerging RNA programs.

With expert insight from:

Engineering Durable, Low-Dose RNA Expression

Attendees learned how next-generation RNA architectures and modifications are extending expression from weeks to months while reducing dose and immune burden.

With expert insight from:

Unlocking Extrahepatic Delivery Beyond LNPs

Attendees discovered novel delivery strategies are enabling redosing and access to previously unreachable tissues using peptide-based and non-LNP systems.

With expert insight from:

Enabling In Vivo CAR-T and Immune Reprogramming with Circular and Self-Amplifying RNA

Attendees discovered how next-generation RNA modalities are replacing complex ex vivo cell therapies with scalable, injectable in vivo CAR-T solutions.

With expert insight from: